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Abstract
Angiotensin-converting enzymes 1 (ACE1) and 2 (ACE2) are key enzymes of the renin-angiotensin system, which act antagonisti-
cally to regulate the levels of angiotensin II (Ang II) and Ang-(1-7). Considerable data show that ACE1 acts on normal skeletal 
muscle functions and architecture. However, little is known about ACE1 levels in muscles with different fiber compositions. 
Furthermore, ACE2 levels in skeletal muscle are not known. Therefore, the purpose of this study was to characterize protein 
expression and ACE1 and ACE2 activities in the soleus and plantaris muscles. Eight-week-old female Wistar rats (N = 8) were 
killed by decapitation and the muscle tissues harvested for biochemical and molecular analyses. ACE1 and ACE2 activities 
were investigated by a fluorometric method using Abz-FRK(Dnp)P-OH and Mca-YVADAPK(Dnp)-OH fluorogenic substrates, 
respectively. ACE1 and ACE2 protein expression was analyzed by Western blot. ACE2 was expressed in the skeletal muscle 
of rats. There was no difference between the soleus (type I) and plantaris (type II) muscles in terms of ACE2 activity (17.35 ± 
1.7 vs 15.09 ± 0.8 uF·min-1·mg-1, respectively) and protein expression. ACE1 activity was higher in the plantaris muscle than 
in the soleus (71.5 ± 3.9 vs 57.9 ± 1.1 uF·min-1·mg-1, respectively). Moreover, a comparative dose-response curve of protein 
expression was established in the soleus and plantaris muscles, which indicated higher ACE1 levels in the plantaris muscle. The 
present findings showed similar ACE2 levels in the soleus and plantaris muscles that might result in a similar Ang II response; 
however, lower ACE1 levels could attenuate Ang II production and reduce bradykinin degradation in the soleus muscle compared 
to the plantaris. These effects should enhance the aerobic capacity necessary for oxidative muscle activity.
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The renin-angiotensin system (RAS) has been identified 
as an important target in the regulation of blood pressure 
as well as fluid and electrolyte balance (1,2). Angiotensin-
converting enzyme (ACE1) converts angiotensin I to angio-
tensin II (Ang II) and inactivates bradykinin, a vasodilator 
peptide, thereby potentiating the vasopressor response 
mediated by Ang II (1,2).
Recent data have demonstrated that the skeletal 
muscle RAS reflects a combination of in situ synthesis 
of RAS components and uptake of these constituents 
from the circulation (3); however, the activity of ACE1 in 
the human skeletal muscle does not correlate with that of 
serum ACE1 (4). Skeletal muscle ACE1 activity has been 
demonstrated in cell membrane fractions and cultured 
myoblasts (5). In addition, RAS components are present 
throughout the skeletal muscle microcirculation, including 
endothelial cells, vascular smooth muscle cells, and other 
vessel-associated cells (6). 
Several studies have shown that ACE1 inhibition pro-
motes morphological and functional alterations such as 
an increased proportion of type I fibers and angiogenesis 
(7,8). Indeed, ACE insertion/deletion polymorphism is clear 
evidence that different ACE1 levels may induce prevalence 
of type I or II fibers associated with skeletal muscle pheno-
type and performance (9,10).
Half a century after the discovery of ACE1, a new ho-
molog of the enzyme, termed ACE2, was identified (11). 
The substrates identified for ACE2 include Ang I and Ang 
II, which are cleaved to a nonapeptide Ang-(1-9) and a 
heptapeptide Ang-(1-7), respectively. The conversion of 
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Ang II to Ang-(1-7) is the preferred pathway, with a 500-
fold greater efficiency compared with the Ang I cleavage 
pathway (11-13).
ACE2 has been implicated in Ang-(1-7) formation, with 
a key role in vasodilation and antiproliferactive effects. 
ACE2 has also been described as an enzyme that works 
as a negative regulator of the RAS, counterbalancing the 
multiple functions of ACE1 (12,13). Together, ACE1 and 
ACE2 counterbalance the Ang II and Ang-(1-7) concen-
tration, permitting a balance between the pressor-trophic 
effects of Ang II and the opposing depressor-antitrophic 
effects of Ang-(1-7).
ACE2 is expressed predominantly in the heart, kidneys, 
and testes, and at a lower level in a wide variety of tissues 
(11-13); however, there have been no publications on the 
ACE2 in skeletal muscle. 
The objective of the present study was to characterize 
the protein expression and activities of ACE1 and ACE2 
in skeletal muscles with different fiber compositions. The 
soleus and plantaris muscles were chosen because they 
are well known to have a distribution of fibers with different 
contractile and metabolic characteristics. We tested two 
hypotheses: 1) that ACE2 is expressed in skeletal muscle 
and 2) that plantaris muscle (predominance of type II fi-
bers) can display higher ACE1 levels compared to soleus 
muscle (predominance of type I fibers) contributing to the 
glycolytic phenotype. Therefore, new information on the 
skeletal muscle RAS and new insights into the actions of 
ACE2 will be provided here.
Material and Methods
Female Wistar rats (180-220 g, N = 8) were used in the 
present investigation and handled according to approved 
Institutional guidelines. Rats were maintained on a 12:12-
h dark-light cycle in a temperature-controlled environment 
(22°C), with free access to standard laboratory chow (Nu-
vital Nutrientes S/A, Brazil) and tap water. The study was 
carried out according to the Ethical Principles in animal 
research adopted by the Brazilian College of Animal Ex-
perimentation (www.cobea.org.br) and was approved by the 
Ethics Committee of the University of São Paulo (protocol 
#2006/04). Rats were killed by decapitation and soleus, 
plantaris, heart, and lungs were harvested for biochemical 
and molecular analyses.
The activity of skeletal muscle ACE1 was determined 
by a fluorometric assay (14) of samples from the soleus 
and plantaris tissues obtained from Wistar rats, frozen in 
liquid nitrogen, and stored at -80°C. Briefly, the homoge-
nate supernatant was incubated for 60 min at 37°C with 
a fluorogenic substrate containing 10 μM Abz-FRK(Dnp)
P-OH (Abz = o-aminobenzoic acid; Dnp = dinitrophenyl) in 
0.1 M Tris-HCl buffer, 50 mM NaCl, and 10 mM ZnCl2, pH 
7.0. The hydrolysis rate of the intramolecularly quenched 
fluorogenic substrate Abz-FRK(Dnp)P-OH was assessed 
with fluorometer λex = 320 nm and λem = 420 nm. Measure-
ments were performed in triplicate, and ACE1 activity values 
are reported as uF·min-1·mg-1. The specificity of the assay 
was demonstrated by complete inhibition of hydrolysis by 0.5 
μM captopril (Sigma-Aldrich, USA). Protein was determined 
by the method of Bradford using bovine serum albumin as 
standard (Bio-Rad Protein Assay, USA). 
The activity of ACE2 was also determined in skel-
etal muscle tissue by a method similar to the one de-
scribed above. The fluorogenic peptide substrate Mca-
YVADAPK(Dnp)-OH (R&D Systems, USA) in 0.2 M Tris-HCl 
buffer, 200 mM NaCl, pH 7.5, which is hydrolyzed with 
high affinity by ACE2, was employed. Captopril, a specific 
ACE1 inhibitor, was used as negative control for the assays 
because it does not inhibit ACE2 activity. The specificity of 
the assay was demonstrated by inhibition of hydrolysis by 
0.1 μM DX600 (Phoenix Pharmaceuticals, USA), a specific 
ACE2 inhibitor.
Soleus and plantaris protein expression was demon-
strated by Western blot. Briefly, liquid nitrogen frozen tissues 
were homogenized in a buffer containing 0.1 M Tris-HCl, 
50 mM NaCl, 1 mM 4-chloromercuribenzoic acid, 9.1 mM 
o-phenanthroline, 1 mM PMSF, and 0.12 mM pepstatin A, 
to prevent the in vitro production and degradation of an-
giotensin peptides and a protease inhibitor cocktail (1:100, 
catalog No. P2714, Sigma-Aldrich). 
Samples were loaded and subjected to SDS-PAGE on 
7.5% polyacrylamide gels. After electrophoresis, proteins 
were electro-transferred to a nitrocellulose membrane 
(Amersham Biosciences, USA). The dose-response curve 
for protein (30, 50, 80, and 100 μg) was used, and transfer 
efficiency was monitored by 0.5% Ponceau S staining of 
the blotted membrane. The latter was then incubated in a 
blocking buffer (5% nonfat dry milk, 10 mM Tris-HCl, pH 
7.6, 150 mM NaCl, and 0.1% Tween 20) for 2 h at room 
temperature, and then incubated overnight at 4°C with a 
mouse anti-ACE (clone 2E2) monoclonal antibody (1:1000; 
Chemicon International, USA) and an anti-ACE2 (T-17) 
polyclonal antibody (1:1000; Santa Cruz Biotechnology 
Inc., USA). Binding of the primary antibody was detected 
with the use of peroxidase-conjugated secondary anti-
mouse antibodies for ACE1 and of anti-goat antibodies for 
ACE2 (1:3000; Zymed Laboratories, USA), for 1 h and 30 
min at room temperature, and developed using enhanced 
chemiluminescence (Amersham Biosciences) detected by 
autoradiography. Quantification analysis of the blots was 
performed with the Scion Image software (based on NIH 
Image, USA). Skeletal muscle α-tubulin expression levels 
were used to control the quantity of protein carried.
Results
Figure 1 shows the characterization of ACE1 in two 
kinds of skeletal muscle, the soleus and the plantaris. ACE1 
activities were 57.9 ± 1.1 and 71.5 ± 3.9 uF·min-1·mg-1, 
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respectively. However, the lung ACE1 activity 
was approximately 10-fold higher (564.7 ± 2.9 
uF·min-1·mg-1) than those detected in both skeletal 
muscles (Figure 1A). Moreover, a comparative 
dose-response curve for ACE1 protein expression 
was confirmed by protein load. Figure 1B depicts 
representative blots of ACE1 in the soleus and 
plantaris muscles as well as in α-tubulin. In agree-
ment, Figure 1C corresponds to the quantitative 
analysis of the dose-response curve for plantaris 
ACE1 protein expression, which provided 8857 
arbitrary units (a.u.) for 30 µg protein, 15,643 a.u. 
for 50 µg, 21,695 a.u. for 80 µg, and 27,177 a.u. for 
100 µg. In the soleus, the dose-response curve for 
ACE1 protein expression gave 5756 a.u. for 30 µg 
protein, 7921 a.u. for 50 µg, 12,386 a.u. for 80 µg, 
and 19,691 a.u. for 100 µg. The rat lung (20,467 
a.u. for 30 µg protein) was used as positive control 
of ACE1 protein expression.
Figure 2 describes the characterization of 
ACE2 in skeletal muscle. The ACE2 activities in 
the soleus and plantaris muscles were 17.35 ± 
1.7 and 15.09 ± 0.8 uF·min-1·mg-1, respectively; 
however, the heart displayed higher ACE2 activ-
ity (24.98 ± 1.7 uF·min-1·mg-1) than both skeletal 
muscles (Figure 2A). Captopril did not block ACE2 
activity, showing that the substrate is specific for 
ACE2. The ACE2 activity was blocked by DX600. 
Figure 2B depicts representative blots of ACE2 
in the soleus and plantaris muscles as well as in 
α-tubulin. In agreement, Figure 2C displays the 
quantitative analysis of the dose-response curve 
for plantaris ACE2 protein expression, namely 
4859 a.u. for 30 µg protein, 9059 a.u. for 50 µg, 
11,539 a.u. for 80 µg, and 15,846 a.u. for 100 µg. 
In the soleus, the dose-response curve for soleus 
ACE2 protein expression yielded similar values, 
more specifically 4082 a.u. for 30 µg protein, 6770 
a.u. for 50 µg, 11,193 a.u. for 80 µg, and 15,374 
a.u. for 100 µg. The rat heart (10,010 a.u. for 30 µg 
protein) was the positive control for ACE2 protein 
expression and exhibited 2-fold higher expression 
of ACE2 compared to skeletal muscle. 
Discussion
The present study identified the activity and 
protein expression of ACE1 and ACE2 in skeletal 
muscles with a predominance of different types 
of fiber. The results demonstrated that 1) ACE2 
is expressed in the skeletal muscle of rats, 2) 
there is no difference between the soleus (type 
I fibers) and the plantaris (type II fibers) in terms 
of ACE2 activity and protein expression, and 3) 
the plantaris displayed higher ACE1 activity and 
Figure 1. ACE1 in the skeletal muscle. A, Skeletal muscle ACE1 activity 
reported as means ± SEM for 8 rats in each group. B, Representative blots 
of plantaris ACE1, soleus ACE1, and α-tubulin. C, Representative figure 
of soleus and plantaris ACE1 protein expression in Wistar rats. Note that 
the plantaris muscle displayed higher activity than the soleus and that both 
muscles presented a dose-response curve for ACE1 protein expression due 
to an increase in protein (30, 50, 80, and 100 µg protein). Also, the plantaris 
muscle presented increased ACE1 protein expression compared to the so-
leus muscle. The rat lung was used as positive control (Ct+) for ACE1 activity 
and protein expression. ACE = angiotensin-converting enzyme. *P < 0.05 
compared to soleus muscle; #P < 0.0001 compared to soleus and plantaris 
muscles; ‡P < 0.01 compared to soleus muscle (Student t-test).
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protein levels than the soleus muscle. 
Fast (type II) and slow (type I) twitch muscle fibers 
exhibit different characteristics with respect to functional 
properties due to differences in the isoforms and in the 
level of expression of most muscle proteins. The 
predominance of oxidative metabolism in the 
soleus muscle, where type I fibers predominate 
and there is a larger amount of capillaries as 
well as higher oxygen support, is important for 
the maintenance of the aerobic capacity of this 
muscle. The lower ACE1 levels in the soleus 
muscle compared with the plantaris muscle might 
contribute to decreased bradykinin degradation, 
thereby potentiating bradykinin concentration, 
a potent activator of the L-arginine-nitric oxide 
pathway. This may promote vasodilation and 
angiogenesis. Indeed, low ACE1 levels have 
previously been shown to cause nitric oxide 
accumulation, thus inducing vasodilation and 
angiogenesis by bradykinin receptors (3,8). In 
agreement, kinins inhibit growth processes, 
consequently leading to high levels of ACE1 in 
the plantaris muscle. The latter is well known for 
containing a larger proportion of type II fibers and 
is responsible for producing greater force per unit 
of cross-sectional area, thereby affecting muscle 
strength through elevated Ang II levels (10). Previ-
ous data regarding the role of Ang II in the control 
of skeletal muscle mass are controversial. Ang 
II has been shown to promote muscle atrophy 
(15); nevertheless, other studies have reported 
that Ang II induces skeletal muscle hypertrophy 
associated with strength gain (16,17). 
The results show that the lower ACE1 activity 
and levels in the soleus muscle compared to the 
plantaris could attenuate Ang II production and 
reduce bradykinin degradation, which favors 
vasodilation, the formation of new vessels, and 
oxygen and substrate delivery. Taken together, 
these effects should enhance the aerobic capacity 
necessary for oxidative muscle activity.
In patients with heart failure, chronic therapy 
with ACE1 inhibitors improves endothelial func-
tion and increases the proportion of slow twitch 
fibers, the oxidative capacity, and the capillary 
density, thereby enhancing aerobic capacity and 
skeletal muscle perfusion (3,7). 
ACE insertion/deletion polymorphism may 
be a possible genetic factor associated with 
excellence in sports (9,10). Human studies have 
identified an increased frequency of the I allele 
in elite endurance athletes, long-distance run-
ners, rowers, and mountaineers, as well as an 
increased occurrence of the D allele with strength 
gains in power performance (3,9,10). An excess 
of the I allele is associated with decreased ACE1 activity 
and prevalence of type I fibers, revealing a relationship 
between this sort of polymorphism and human performance 
in endurance sports (3,9). In contrast, the D allele is asso-
Figure 2. ACE2 in the skeletal muscle. A, Skeletal muscle ACE2 activity 
reported as means ± SEM for 8 rats in each group. B, Representative blots 
of plantaris ACE2, soleus ACE2, and α-tubulin. C, Representative figure of 
soleus and plantaris ACE2 protein expression in Wistar rats. Note that the 
soleus and plantaris muscles displayed similar ACE2 activity and that both 
muscles presented a dose-response curve for ACE2 protein expression due 
to an increase in protein (30, 50, 80, and 100 µg of protein). The rat heart 
was used as positive control (Ct+) for ACE2 activity and protein expression. 
ACE = angiotensin-converting enzyme. †P < 0.05 compared to soleus and 
plantaris muscles; ‡P < 0.01 compared to soleus muscle (Student t-test).
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The discovery of ACE2 in 2000 (11) and our identifica-
tion of this enzyme in skeletal muscle broaden the concept 
of tissue RAS (1,2). In hypertension, lower ACE2 mRNA 
and protein levels culminate in elevated Ang II levels. This 
effect could reduce myocardial blood flow preferentially 
via coronary vasoconstriction or microcirculatory dysfunc-
tion. ACE2 is enhanced by ACE1 inhibitors or angiotensin 
receptor blockers (12,18). 
Crackower et al. (13) showed that deletion of ACE2 in 
mice results in elevated cardiac and plasma Ang II together 
with impaired cardiac contractility and left ventricle dilation. 
Studies have proposed that ACE2 might protect against CVD 
by diminishing Ang II concentration, consequently resulting 
in augmented Ang-(1-7) generation (19). This implies that 
there is a balance between ACE1 and ACE2 in the control 
of the Ang II and Ang-(1-7) levels. 
Cardiac overexpression of ACE2 exerts a protective influ-
ence on the heart during myocardial infarction by preserving 
cardiac function, left ventricle wall motion and contractility, 
and by attenuating left ventricle wall thinning (20). 
The significance of the present study is that, by char-
acterization of ACE2 in skeletal muscle, future therapies 
targeting ACE2 might be developed for the treatment of 
peripheral abnormalities in skeletal muscle mediated by 
hypertension and other CVD such as vasomotor tonus 
imbalance induced by high peripheral vasoconstriction, 
increased wall-to-lumen vascular ratio, and microvascular 
rarefaction. Moreover, the present results might have im-
plications in sports performance.
This study brings new insight into the role of ACE1 in 
skeletal muscle and presents the first report on ACE2 ac-
tivity and protein expression in skeletal muscle. As ACE2 
differs in its specificity and physiological role from ACE1, 
these results might be relevant for the treatment of skeletal 
muscle pathologies in CVD. 
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